Vicki Moore is a contributing writer at Hematology Advisor. With a PhD in biology from Arizona State University, Vicki specializes in medical writing with a focus on hematology and oncology, while also exploring topics such as immunotherapy, palliative care, and public health. Her work has been featured in various reputable outlets, including Infectious Disease Advisor, NewsBreak, and Oncology Nurse Advisor.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Vicki Moore's coverage primarily focuses on citing data in the healthcare and pharmaceutical space, with an emphasis on oncology research, cancer treatments, patient preferences, treatment outcomes, and medical advancements. Given her focus on citing data extensively, she would likely be interested in pitches that provide access to or insights from new studies or clinical trials related to these topics.
She seems dedicated to providing factual information backed by solid evidence. Therefore, sources reaching out should have credible expertise in their respective fields and be able to offer scientific backing for any claims made.
Vicki does not seem to maintain a specific geographic focus but instead appears focused on incorporating the most recent findings within the healthcare and pharmaceutical domain regardless of location.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Vicki Moore
In this study, the researchers aimed to identify 5- and 10-year RS outcomes for individuals aged younger than 20 years at the time of a cancer diagnosis, based on data obtained from the National Program of Cancer Registries for 2001 to 2021.
By: Vicki Moore
In patients with transfusion-dependent β-thalassemia (TDT) without cardiac iron overload, noninvasive approaches may have potential to identify early exercise-induced diastolic dysfunction. This is according to the findings of a new study published in the Journal of Translational Medicine.
By: Vicki Moore
In this study, researchers aimed to evaluate patterns of engagement with health-related content on social media among US adults both with and without chronic conditions.
By: Vicki Moore
Garitaonaindia Y, Witteveen S, Dionisio E, et al. Prognostic dynamics of pathological complete response and ctDNA clearance after neoadjuvant/perioperative
By: Vicki Moore
| Publish Date Among Ewing sarcoma (EWS) survivors, rates of late mortality, subsequent malignant neoplasms (SMNs), and certain
By: Vicki Moore
| Publish Date For women who are unaffected carriers of BRCA1 pathogenic variants, breast cancer risk management approaches have
By: Vicki Moore
Twice-daily (BID) deferiprone (DFP) appeared well-tolerated in a real-world study that included patients with thalassemia, sickle cell disease (SCD), or other anemias and transfusional iron overload. Findings from the study were reported in the journal Blood Advances.
By: Vicki Moore
| Publish Date Reducing or omitting dexamethasone (DEX) was found to be noninferior to treatment including standard DEX for patients
By: Vicki Moore
| Publish Date The anti–lymphocyte activation gene 3 (LAG-3) antibody relatlimab demonstrated acceptable safety with or without
By: Vicki Moore
Liu W, Liu J, Su Y, et al. Factors influencing fear of cancer recurrence in breast cancer survivors: a multicenter cross-sectional study BMC Womens Health . Published online June 17, 2026. doi:10.1186/s12905-026-04614-9
